Compare Crispr Therapeutics AG (CRSP) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nutrien Ltd — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Nutrien Ltd trades at $66.6 (market cap $32.05B). The key difference: Nutrien Ltd is far larger — about 6.1× Crispr Therapeutics AG's market cap, and Nutrien Ltd pays a 3.27% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NTR | |
|---|---|---|
Market Cap | $5.23B | $32.05B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $83.94 |
52-Week Low | $44.34 | $53.64 |
Enterprise Value | $3.65B | $43.86B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Nutrien (NTR) trades at $66.85, up 0.81% today, with a bearish technical signal despite neutral oscillators. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher potash prices. The company maintains a stable dividend of $0.55 per share and shows improving net income margins, though cash flow trends have weakened. Analyst consensus is bullish with a $76.17 price target, highlighting structural advantages in nitrogen assets.
The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and volatile earnings pose risks. Key opportunities include exposure to agricultural cycles and cost advantages; risks involve input cost pressures and execution challenges in a competitive fertilizer market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
